Molecular Partners

Molecular Partners

Biotechnologieforschung

Schlieren-Zürich, Zürich Area 10.598 Follower:innen

Pioneering DARPin Therapeutics for Patients

Info

Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA.

Branche
Biotechnologieforschung
Größe
51–200 Beschäftigte
Hauptsitz
Schlieren-Zürich, Zürich Area
Art
Kapitalgesellschaft (AG, GmbH, UG etc.)
Gegründet
2004
Spezialgebiete
DARPins, Oncology, Immuno-Oncology, Radiopharmaceuticals, Immunology and other indications, Virology, Ophthalmology, Intellectual property of DARPins, Repeat proteins and protein engineering und Collaborations with other leading pharmaceutical companies

Orte

Beschäftigte von Molecular Partners

Updates

Ähnliche Seiten

Finanzierung